← Back

Wire · operational-macro

US FDA declines to approve Capricor's Duchenne treatment citing unreliable trial data; shares slump

Published

21 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at reuters.com →

◆ Verified

Fusion42 · 21 November 2026 · Fusion42 review

The US FDA declined to approve Capricor Therapeutics' experimental cell therapy deramiocel for Duchenne muscular dystrophy due to serious data integrity issues in the clinical trial, causing the company's shares to plunge 77%.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 12 Nov 2026 and 21 Nov 2026.

◆ ◆ The Wire takeaway

You must brace for tighter scrutiny on clinical trial data reliability as the FDA rejects treatments with questionable data. This rejection opens the field for rivals who can deliver robust evidence for Duchenne therapies.

◆ Coverage

2 sources · first reported 12 Nov 2026 · latest 21 Nov 2026

◆ Related on Wire

◆ Topics

Biotechus-fdadrug-approvalclinical-trialsbiotechduchenne-muscular-dystrophy